Top of this page
Skip navigation, go straight to the content

At UCB our sense of purpose is to help people suffering from severe central nervous system or immunological disorders lead normal, everyday lives. Our ambition is to offer them innovative new medicines and ground-breaking solutions that go beyond the drug. We are committed to enabling cutting-edge scientific research that is driven by the patients' needs.
UCB, headquartered in Brussels, Belgium, is a global biopharma company with a team of more than 8,000 talented employees, a strong market presence in about 40 countries, € 3.2 billion in revenue (2011) and numerous strategic partnerships across the industry.
UCB and patients: partners in innovation
Posted by Xavier Hormaechea, Public Affairs 11-May-2012
Researchers explore ‘personalised’ treatments
Posted by Ingrid Pansar, Medical Immunology Northern Europe 11-May-2012
It’s World Lupus Day
Posted by Kristel Santens, New Product Planning & Portfolio Management 10-May-2012
UCB is listed on Euronext Brussels
(symbol: UCB)